The core of the I-SPY 2 platform trial for high-risk breast cancer is a Bayesian statistics-driven adaptive design that evaluates single investigational drugs and biologics versus standard of care in the neo-adjuvant setting. I-SPY-2 has shown that treatments that eliminate tumor prior to surgery dramatically improves survival in high-risk early stage breast cancer patients. The I-SPY 2 program is now continuing to innovate and push trial design continuous learning through individual optimization. Over the next five years, our goal is to get 90% of patients cured, with less toxic therapies. By rapidly and efficiently testing new drugs and combinations, we will ensure that each patient receives the most appropriate therapy for their disease - and in doing so, also reduces the time and cost of drug/biologics development. New findings from I-SPY 2, along with the next stage of this patient-focused, transformative trial will be presented.
Join our distinguished panel of experts including senior leadership from the FDA, the I-SPY 2 team, and breast cancer survivors as we announce major advances from the trial to date and look to the future of innovation in these patient-centered clinical trials.